Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes.
Hematopoetic cell transplantation
Proteomics
biomarkers
graft-versus-host disease
validation
Journal
Proteomics. Clinical applications
ISSN: 1862-8354
Titre abrégé: Proteomics Clin Appl
Pays: Germany
ID NLM: 101298608
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
08
09
2018
revised:
28
09
2018
pubmed:
12
10
2018
medline:
3
5
2019
entrez:
12
10
2018
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective form of tumor immunotherapy available to date. However, while HSCT can induce beneficial graft-versus-leukemia (GVL) effect, the adverse effect of graft-versus-host disease (GVHD), which is closely linked to GVL, is the major source of morbidity and mortality following HSCT. Until recently, available diagnostic and staging tools frequently fail to identify those at higher risk of disease progression or death. Furthermore, there are shortcomings in the prediction of the need for therapeutic interventions or the response rates to different forms of therapy. The past decade has been characterized by an explosive evolution of proteomics technologies, largely due to important advances in high-throughput MS instruments and bioinformatics. Building on these opportunities, blood biomarkers have been identified and validated both as promising diagnostic tools, prognostic tools that risk-stratify patients before future occurrence of GVHD and as predictive tools for responsiveness to GVHD therapy and non-relapse mortality. These biomarkers might facilitate timely and selective therapeutic intervention. This review summarizes current information on clinical proteomics for GVHD as well as other complications following HSCT. Finally, it proposes future directions for the translation of clinical proteomics to discovery of new potential therapeutic targets to the development of drugs.
Identifiants
pubmed: 30307119
doi: 10.1002/prca.201800145
pmc: PMC6440827
mid: NIHMS1017819
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1800145Subventions
Organisme : Leukemia & Lymphoma Society
ID : 1293-15
Pays : International
Organisme : NCATS NIH HHS
ID : UL1 TR001108
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL139934
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD074587
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA168814
Pays : United States
Informations de copyright
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
J Am Soc Nephrol. 2004 Jan;15(1):219-27
pubmed: 14694176
J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61
pubmed: 11459866
Blood. 2004 Jul 15;104(2):340-9
pubmed: 15054046
Biostatistics. 2011 Jan;12(1):87-101
pubmed: 20639522
J Proteome Res. 2011 Jan 7;10(1):66-84
pubmed: 20715861
Blood. 2012 Apr 19;119(16):3854-60
pubmed: 22383800
Blood. 2017 Jan 12;129(2):162-170
pubmed: 27827824
Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):33-8
pubmed: 19147075
Leukemia. 2015 Oct;29(10):2062-8
pubmed: 26228813
Ann Transl Med. 2016 Dec;4(24):500
pubmed: 28149862
Haematologica. 2017 May;102(5):932-940
pubmed: 28126963
Mol Cell Proteomics. 2002 Nov;1(11):845-67
pubmed: 12488461
Epidemiology. 2005 Sep;16(5):598-603
pubmed: 16135934
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Immunity. 2013 Dec 12;39(6):1003-18
pubmed: 24332029
Clin Pharmacol Ther. 2001 Mar;69(3):89-95
pubmed: 11240971
Blood. 2018 May 17;131(20):2193-2204
pubmed: 29622549
J Proteome Res. 2006 Aug;5(8):2009-18
pubmed: 16889424
Blood. 2009 Jan 8;113(2):273-8
pubmed: 18832652
N Engl J Med. 2010 Sep 16;363(12):1117-27
pubmed: 20843246
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Sci Transl Med. 2010 Aug 25;2(46):46ps42
pubmed: 20739680
Blood. 2015 Jan 1;125(1):199-205
pubmed: 25377785
Proteomics Clin Appl. 2007 Jan 1;1(1):73-88
pubmed: 20204147
Biol Blood Marrow Transplant. 2013 Sep;19(9):1323-30
pubmed: 23791624
Nat Rev Cancer. 2013 Jul;13(7):439
pubmed: 23722289
Bioinformatics. 2006 Nov 15;22(22):2830-2
pubmed: 16877754
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):202-7
pubmed: 24344260
Blood. 2014 Aug 14;124(7):1174-82
pubmed: 24939656
Front Immunol. 2017 Apr 24;8:475
pubmed: 28484466
Biol Blood Marrow Transplant. 2017 Jul;23(7):1122-1127
pubmed: 28344057
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Blood. 2012 Nov 15;120(20):4246-55
pubmed: 23012327
Cytokine. 2015 Mar;72(1):105-8
pubmed: 25573803
Proteomics. 2011 Mar;11(6):1160-71
pubmed: 21328537
Proteomics Clin Appl. 2007 Aug;1(8):780-91
pubmed: 21136734
Biol Blood Marrow Transplant. 2015 Aug;21(8):1373-83
pubmed: 25977230
Leukemia. 2014 Apr;28(4):842-52
pubmed: 23842427
Blood. 2011 Dec 15;118(25):6702-8
pubmed: 21979939
Front Immunol. 2017 Jun 19;8:717
pubmed: 28674539
Mol Cell Proteomics. 2011 Sep;10(9):M111.011015
pubmed: 21642640
Sci Transl Med. 2010 Jan 6;2(13):13ra2
pubmed: 20371463
Blood. 2016 Feb 4;127(5):646-57
pubmed: 26670634
Blood. 2007 Dec 15;110(13):4535-42
pubmed: 17702900
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S146-51
pubmed: 19836455
J Clin Oncol. 2016 Aug 1;34(22):2583-90
pubmed: 27217465
Blood. 2006 Oct 15;108(8):2867-73
pubmed: 16788100
Blood. 2012 Mar 22;119(12):2960-3
pubmed: 22286196
Biol Blood Marrow Transplant. 2015 May;21(5):780-92
pubmed: 25644957
Blood. 2015 Mar 12;125(11):1703-7
pubmed: 25645355
Lancet Oncol. 2014 Dec;15(13):1451-1459
pubmed: 25456364
Nat Immunol. 2014 Dec;15(12):1095-7
pubmed: 25396342
Blood. 2014 Jan 30;123(5):786-93
pubmed: 24363401
Biol Blood Marrow Transplant. 2015 Jan;21(1):16-23
pubmed: 25452031
Biol Blood Marrow Transplant. 2015 Oct;21(10):1739-45
pubmed: 26172478
PLoS One. 2016 Apr 13;11(4):e0153207
pubmed: 27074138
Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234
pubmed: 27713092
J Am Acad Dermatol. 2013 Aug;69(2):e102-3
pubmed: 23866880
J Clin Oncol. 2017 May 20;35(15):1650-1659
pubmed: 28296584
FEBS Lett. 1989 Dec 4;258(2):301-4
pubmed: 2532153
Biol Blood Marrow Transplant. 2016 Sep;22(9):1552-1564
pubmed: 27158050
Blood. 2015 Jul 2;126(1):113-20
pubmed: 25987657
Leukemia. 2017 Mar;31(3):654-662
pubmed: 27677743
J Clin Invest. 2010 May;120(5):1479-93
pubmed: 20389017
Mol Cell Proteomics. 2004 Dec;3(12):1154-69
pubmed: 15385600
Bone Marrow Transplant. 2017 Jul;52(7):1010-1015
pubmed: 28481353
Methods. 2015 Jul 1;82:55-63
pubmed: 25979346
Biol Blood Marrow Transplant. 2017 Mar;23(3):529-532
pubmed: 28013014
Biol Blood Marrow Transplant. 2018 Apr;24(4):678-686
pubmed: 29223372
Blood. 2016 Jun 16;127(24):3082-91
pubmed: 27020088
Blood. 2014 Jun 12;123(24):3832-42
pubmed: 24711661
Biol Blood Marrow Transplant. 2018 Jul;24(7):1322-1340
pubmed: 29471034
Mol Cell Proteomics. 2003 Oct;2(10):1096-103
pubmed: 12917320
Lancet Haematol. 2015 Jan;2(1):e4-5
pubmed: 26687427
Biol Blood Marrow Transplant. 2017 Aug;23(8):1250-1256
pubmed: 28455006
J Invest Dermatol. 2015 Apr;135(4):999-1006
pubmed: 25405322
N Engl J Med. 2013 Aug 8;369(6):529-39
pubmed: 23924003
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 1;877(13):1229-39
pubmed: 19041286
Proteomics. 2005 Aug;5(13):3262-77
pubmed: 16052621
Lancet. 2003 Jan 4;361(9351):71
pubmed: 12517476
Rheumatology (Oxford). 2015 Dec;54(12):2134-44
pubmed: 26209330
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2770-7
pubmed: 24979804
J Invest Dermatol. 2017 Jan;137(1):62-70
pubmed: 27640094
Blood. 2015 Oct 1;126(14):1723-8
pubmed: 26209659
Clin Cancer Res. 2007 Oct 15;13(20):6107-14
pubmed: 17947475
Lancet Haematol. 2015 Jan;2(1):e21-9
pubmed: 26687425
Biol Blood Marrow Transplant. 2014 Nov;20(11):1861-4
pubmed: 25017764
JCI Insight. 2017 Feb 9;2(3):e89798
pubmed: 28194439
Lancet Haematol. 2017 Jul;4(7):e305-e306
pubmed: 28602584
Blood. 2012 Aug 9;120(6):1202-9
pubmed: 22718840
Sci Transl Med. 2015 Oct 7;7(308):308ra160
pubmed: 26446957
N Engl J Med. 2017 Mar 23;376(12):1189-1190
pubmed: 28328331
J Natl Cancer Inst. 2003 Apr 2;95(7):511-5
pubmed: 12671018